Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the cytotoxic potency of small molecules, and approvals now cover hematologic malignancies and solid tumors. The same structure that makes them work complicates preclinical-to-clinical translation: an ADC is an antibody, a linker, and a payload, and each part behaves differently in vivo.
At Prisys Biotech, the PK/PD translational framework is built to characterize ADC behavior in vivo, support dose selection, and sharpen clinical prediction.
Key Challenges in ADC Development
Complex Pharmacokinetics
ADC pharmacokinetics (PK) depend on antibody stability, linker chemistry, payload physicochemical properties, and in vivo deconjugation. The result is several analytes that have to be measured in parallel: conjugated drug, total antibody, and free payload.
Safety and Toxicity Risks
ADC safety reflects more than pharmacological activity. Off-target effects, biophysical properties, and immunogenicity risk all enter the assessment, and hematological toxicities such as thrombocytopenia and neutropenia are particularly important for translational evaluation.
PK/PD Relationship
Efficacy depends on reaching sufficient exposure at the target site while keeping systemic toxicity in check. Quantitative PK/PD modeling connects drug concentration with pharmacological response and supports prediction of human outcomes.
Immunogenicity Considerations
Anti-drug antibody (ADA) formation can alter clearance, distribution, and efficacy, so preclinical assessment has to monitor it.
Translational PK/PD Framework for ADCs
Prisys Biotech combines non-human primate (NHP) models, bioanalytical methods, and computational modeling in one framework:
Bioanalytical Characterization
Affinity capture LC-MS/MS tracks DAR (drug-to-antibody ratio) distribution, linker stability, and payload release, which shows how the drug is modified in vivo.
Species Selection and Scaling
NHPs remain the species used for ADC PK scaling to humans. Simple allometric scaling often holds for antibody-dominated kinetics, though linker and payload chemistry can introduce variability that requires refinement.
FIH Dose Estimation
First-in-human (FIH) dose design usually combines large-molecule approaches (HNSTD, NOAEL) with small-molecule metrics (STD10, BSA scaling), and applies conservative safety factors for novel payloads.
Efficacy Dose Prediction
Modeling runs from empirical body-weight-based extrapolation through semi-mechanistic tumor growth inhibition models to multiscale quantitative systems pharmacology (QSP) frameworks, and it guides effective dose selection and regimen optimization.
Safety Translation
Hematological toxicities are modeled across species with protein-binding differences and marrow sensitivity included. NHP data then refine human risk prediction and inform mitigation strategies.
Why Prisys Biotech?
Expertise in NHP Pharmacology: cynomolgus monkey PK/PD studies keep ADC programs translatable, and bioanalysis on the same platforms quantifies conjugated drug, total antibody, and free payload at high sensitivity. Semi-mechanistic and mechanistic PK/PD models predict human dosing, efficacy, and safety. Safety evaluation covers hematological toxicity and immunogenicity risk, and preclinical findings are aligned with the regulatory expectations that govern IND-enabling studies.
Conclusion
ADC development needs a translational strategy that holds pharmacology, safety, and modeling together. Prisys Biotech runs that work: PK/PD data from NHP studies, predictive modeling, and the interpretation that connects preclinical findings to clinical outcomes. The goal is a preclinical package that supports the next clinical decision.
